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Abstract 
Multiple sclerosis (MS) is the most common inflammatory disorder of the central nervous system (CNS) in 
young adults. When MS is not treated, it leads to irreversible and severe disability.  The etiology of MS and its 
pathogenesis are not fully understood. The recent discovery that MS-associated genetic variants code for 
molecules related to the function of specific immune cell subsets is consistent with the concept of MS as a 
prototypic, T cell-mediated autoimmune disease targeting the CNS.  While the therapeutic efficacy of the 
currently available immunomodulatory therapies further strengthen this concept, differences observed in 
responses to MS treatment as well as additional clinical and imaging observations have also shown that the 
autoimmune pathogenesis underlying MS is much more complex than previously thought. There is therefore 
an unmet need for continued detailed phenotypic and functional analysis of disease-relevant adaptive immune 
cells and tissues directly derived from MS patients to unravel the immune etiology of MS in its entire 
complexity. In this review, we will discuss the currently available MS treatment options and approved drugs, 
including how they have contributed to the understanding of the immune pathology of this autoimmune 
disease. 
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Introduction - Multiple sclerosis as an autoimmune disease 
 
MS is considered a prototypic organ-specific autoimmune disease targeting the CNS with inflammatory lesions, 
demyelination, axonal/neuronal damage and metabolic changes [1, 2]. Relapsing-remitting and secondary 
progressive MS (RRMS, SPMS) are the two most frequent forms of MS, which often affect young adults 
between 20 and 40 years of age, and women 3 times more often than men [3]. Typical clinical signs include 
temporary loss of vision, sensory and motor problems, but also fatigue, neurocognitive changes, and 
impairment of bladder-, bowel- and sexual functions. During the relapsing-remitting phase neurological 
deficits, which occur in bouts and may last from days to a few weeks, usually disappear again, but after several 
years, disability gradually builds up. Depending on the individual course this secondary progressive disease with 
continuously increasing disability may never set in, but often starts after 15-20 years of RRMS. In a small 
percentage of patients such a progressive course is seen from the beginning, which is referred to as primary 
progressive MS (PPMS) and seen in females and males with equal frequency [3].  
 
Evidence for an autoimmune pathogenesis of MS was shown in its animal model, experimental autoimmune 
encephalomyelitis (EAE) (summarized in [4, 5]). Studies in EAE models in mouse, rat, guinea pig and monkey 
have led to a better understanding of some aspects of MS biology and have in some instances helped to 
develop the current MS therapies, two of which target immune cell trafficking (see below). EAE is induced by 
subcutaneous immunization of susceptible naive recipients with CNS myelin antigens in complete Freund’s 
adjuvant or by the adoptive transfer of freshly activated neuroantigen/myelin-specific CD4+ T helper 1 (Th1) or 
Th17 cell blasts (summarized in [5, 6]). Thus, autoreactive CD4+ T cells are sufficient to induce an inflammatory 
demyelinating disease that is similar to MS. Nevertheless, several treatments that were successful in EAE failed 
in MS trials, underlining the fact that MS pathogenesis is more complex than that mimicked by the current EAE 
models (summarized in [7]). 
 
Research of the immune system in MS patients has established that MS is an autoimmune disease with T cells, 
B cells, and probably also autoantibodies as the most important factors contributing to its 
immunopathogenesis [1, 8, 9]. Autoreactive CD4+ T cells with Th1 (secreting IFN-γ) or Th1* (secreting IFN-γ and 
IL-17), or those secreting IFN-γ and GM-CSF [1, 10, 11], play an important role in MS, which is partly supported 
by data from the EAE models [6]. In addition, high avidity myelin-specific CD4+ T cells are directed against 
immunodominant peptides of myelin basic protein (MBP), proteolipid protein (PLP) and myelin 
oligodendrocyte glycoprotein (MOG), and several peptide epitopes are similar or identical to those that are 
most often used to induce EAE [1]. However, it is likely that additional target antigens will be discovered in the 
future. CD4+ Th2 cells (secreting IL-4, L-5 and IL-13) have recently been described in pattern II MS [12], an 
antibody-mediated subform of MS [13]. The transgenic expression of MBP-specific T cell receptors (TCRs) and 
the MS-associated HLA-class II molecules in mice [14-16], but particularly also findings along the treatments of 
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MS ([17]; see in detail below) have highlighted the importance of CD4+ T cells as central pathogenic factor in 
MS. Further evidence is the strong association of MS with the DR15 haplotype. This HLA-class association was 
described in 1972 as the first for any autoimmune disease [18], and it is now firmly established as the most 
important genetic risk factor of MS [19]. Beyond the DR15 haplotype and the observation of HLA-A2 as a 
protective and HLA-A3 as risk-increasing HLA-class I allele, genetic research has been very successful during the 
last ten years. Several large genome-wide association studies (GWAS) have identified more than 150 common 
genetic variants (single nucleotide polymorphisms; SNPs) [19, 20]. Interestingly, the vast majority of these 
genetic variants include cytokines and cytokine receptors, transcription factors, adhesion and costimulatory 
molecules linked to the immune system [19, 20].  However, autoreactive CD4+ T cells are not the only "player" 
in MS. CD8+ T cells are found more abundantly than CD4+ cells in MS brain lesions [21], and recently a few CD8+ 
cell-mediated EAE models have been developed [22]. Since the target cells of the autoimmune process in MS, 
oligodendrocytes and neurons, do not express HLA-class II, but HLA-class I molecules, CD8+ T cells are more 
likely to be the main effectors that lead to tissue damage [23, 24]. Moreover, a role for myelin-specific 
autoantibodies has long been suspected, and more than 30% of MS patients show serum and/or CSF antibodies 
that are able to damage myelin and/or axons [25]. Among the potential target antigens of autoantibodies in 
MS MOG [26], neurofascin [27], contactin-2 [28], the potassium channel, KIR-4.1 [29], are the most studied;  
however, further research is needed. Experience with B cell-depleting antibodies indicates that the antigen-
presenting function of B cells may be as, or even more, important as autoantibody formation in driving MS [30, 
31]. Innate immune cells such as macrophages, dendritic cells (DCs), microglia and natural killer (NK) cells are 
involved in MS development at various stages of the immune activation as effector or regulatory cells, and 
during the chronic compartmentalized inflammation in the brain, which characterizes the chronic progressive 
stage of MS [32].  
Treatments of MS  
 
As already noted above, the various treatments of MS deserve particular mentioning not only because they 
have changed clinical practice and can be considered a continuing "success story" in the field of neurological 
diseases, but also because they have taught us important lessons about the immune mechanisms of MS. The 
fact that immunomodulatory treatments reduce relapse rates in MS by up to 60% and have even more 
profound effects, when magnetic resonance imaging (MRI) is used to measure disease activity [30, 33-35], 
underscores that MS is an immune-mediated disease. Until the late 1980s no treatment for MS was available 
other than giving steroids during acute MS exacerbations. While relapse treatment has not changed, there are 
now 10 drugs that have been approved for the various forms of MS from the first clinical manifestation 
(clinically isolated syndrome, CIS) over RRMS to SPMS [36], and, for the first time also for PPMS. Each one of 
the currently available treatments, and a few additional ones that have not been approved, are briefly outlined 
below and highlight the lessons that we have learnt from them (Table 1 and Figure 1).  
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Interferon-beta (IFN-β) 
 
Five different versions and subcutaneous application forms of IFN-β have been approved between 1993 and 
2015 for CIS, RRMS and SPMS. IFN-β was originally tested in MS patients as intrathecal injections with the 
hypothesis that viral infections cause or sustain MS [37]. It had not been explored in the EAE model prior to 
testing in MS patients. IFN-β reduces relapse rates by approximately 30% and is very well tolerated  [38] (see 
Table 1 and Fig. 1). Since its first use, several hundred studies have examined the mechanisms of IFN-β 
treatment in MS. The most important mechanisms of action for IFN-β which have been shown include: 
stabilization of the blood-brain barrier (BBB) by blocking matrix metalloproteases in in vitro models and in 
treated MS patients [39-41], the downregulation of HLA-class II molecules and antigen presentation on glial 
cells and B cells in vitro [42], and the inhibition of proinflammatory and upregulation of Th2 cytokines by T cells 
of IFN-β-treated patients [43, 44], although some of these observations remain controversial [45]. Whether 
IFN-β antiviral activity also contributes to the clinical effects is not clear, but more than 20 years of clinical use 
have shown that IFN-β treatment does not lead to any compromise of the immune system with respect to 
protection against viral, bacterial or fungal infections.  
 
Glatiramer-acetate (GA) 
 
Sela and colleagues developed random copolymers with a specific amino acid composition in order to mimic 
myelin proteins and to induce EAE [46]. Surprisingly, glatiramer-acetate (GA), which is composed of 
polypeptides with the amino acids glutamate, lysine, alanine and tyrosine in random order and a fixed molar 
ratio of 1.9 to 4.7 to 6.0 to 1.0, did not induce but rather improve EAE [46]. After a tortuous clinical 
development, GA was first approved in 1996. GA needs to be injected subcutaneously, inhibits relapse rates by 
approximately 30%, and is very well tolerated [47].  Several studies have investigated the immunomodulatory 
effects of GA. Among them, GA interferes with antigen presentation in the EAE model and human myelin-
specific T cell clones [48], shifts the proinflammatory T-cell response in MS to one that is immunomodulatory 
and Th2-like in the EAE model [49] and also in T cells of GA-treated patients [50], induces regulatory CD8+ T 
cells in GA-treated patients [51], shifts the phenotype of monocytes from a proinflammatory (M1) to a 
regulatory (M2) type in EAE [52], and induces the production of neurotrophic factors such as brain-derived 
neurotrophic factor (BDNF)[53-55] [47] (see Table 1 and Fig. 1). Which of these GA immunomodulatory effects 
are most important in reducing the disease activity in MS is difficult to assess, but its activity profile is unique 
and it also does not compromise protective immune responses. 
 
Anti-α4-integrin (natalizumab) 
 
Seminal findings by Yednock et al. demonstrated in 1992 that blocking very late antigen-4 (VLA-4; α4β1-
integrin)-mediated adhesion of immune cells profoundly inhibits EAE activity [56]. Prior to the in vivo EAE 
experiments they tested several monoclonal antibodies for their ability to inhibit adhesion of cells derived from 
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a monocytic cell line to cerebral vessels in inflamed EAE brain tissue and showed that attachment of activated 
lymphocytes and monocytes is inhibited by antibodies against α4β1 integrin [56] (see Table 1 and Fig. 1). 
Subsequent studies from other groups confirmed these findings and identified VCAM-1 as the vascular ligand 
for VLA-4 [57]. A humanized α4-integrin blocking IgG4 antibody (natalizumab) was subsequently developed for 
the treatment of RRMS and shown to be efficacious in blocking relapse rates to a much higher extent than IFN-
β and GA [33]. Natalizumab is very well tolerated except for one adverse event, JC polyoma virus (JCV)-
associated progressive multifocal leukoencephalopathy (PML), an opportunistic and often fatal infection of the 
brain. Approximately 600 cases of PML have been reported in natalizumab-treated MS patients until now, and 
more than 20% of patients have died [58]. PML occurs in situations of hereditary or acquired 
immunocompromise [59]. Natalizumab efficiently prevents activated CD4+ T cells from entering the CNS, and it 
is currently believed that this mechanism, which is desired in MS, compromises physiological immune 
surveillance of the brain [60]. Furthermore, inhibition of VLA-4/VCAM-1 interactions by natalizumab also 
induces the release of hematopoietic precursor cells and marginal zone B cells from their physiological niches 
in bone marrow and lymphoid organs into the peripheral blood [61]. To which extent the latter mechanisms 
contribute to PML remains to be shown. Risk stratification with anti-JCV antibody titers has helped in 
determining, in which patients the treatment is relatively safe, but, despite the high efficacy and overall very 
good tolerability, the risk of PML is a serious problem when treating MS patients with natalizumab. Ongoing 
research tries to identify why natalizumab, which targets a very specific cell-cell interaction, contributes to such 
a rare viral infection [62]. 
 
The sphingosin 1-phosphate receptor agonist fingolimod 
  
Fingolimod, a derivative of the fungal antibiotic myriocin, is a functional antagonist of four of the five 
sphingosin-1 phosphate receptors (S1PR), which are expressed by many cells including immune cells [63, 64]. 
Fingolimod was first tested in transplant models, before it was developed for MS [65]. Early studies in the EAE 
model demonstrated that EAE is ameliorated and that fingolimod inhibits the recirculation of T cells to the CNS 
[66]. After successful clinical development [67], fingolimod was approved as the first oral drug in MS in 2011. It 
is more effective with respect to reducing relapse rates in RRMS than IFN-β and GA, but less than natalizumab 
[67]. Fingolimod acts by a different mechanism of action than all previously mentioned compounds. Fingolimod 
binds to S1PRs and leads to their internalization and degradation. Since the S1P-mediated signal is necessary 
for egress of CCR7-expressing lymphocytes from lymph nodes [68], fingolimod leads to trapping of naive and 
central memory cells in lymph nodes, while CCR7neg T effector memory and effector memory recently activated 
T cells (TEMRA) are not affected [63] (see Table 1 and Fig. 1). The result is a relative lymphopenia and change in 
composition of peripheral lymphocytes. This effect of fingolimod is considered the main mechanism of action 
in MS; however, multiple other activities on immune cells and CNS including the BBB have been demonstrated. 
Interestingly, fingolimod also leads to a subtle defect in immunocompetence regarding control of viral infection 
[69]. Only two herpes viruses that reside in cells of the nervous system, i.e. varizella zoster virus (VZV) and 
herpes simplex virus 1 (HSV1), are affected by fingolimod treatment [69, 70]. More frequent reactivation of 
 7 
these two viruses from the latent state and, in a few cases, severe generalized VZV infection and HSV1 
encephalitis even with fatal outcome have occurred [70]. PML has been observed as well under fingolimod 
treatment, but only in very few cases compared with natalizumab [71]. 
 
Teriflunomide 
 
Teriflunomide is a metabolite of leflunomide [72, 73].  Teriflunomide was approved in 2012 as oral drug for 
treating RRMS. Teriflunomide reduces the relapse rates similar to IFN-β and GA treatments [74], but is not as 
active as fingolimod and dimethylfumarate (DMF) [67, 75]. The main mechanism of action is the inhibition of 
dihydro-orotate-synthetase, a key enzyme in the synthesis pathway of pyrimidine nucleotides [76] (see Table 1 
and Fig. 1). As a result teriflunomide inhibits the proliferation of activated T lymphocytes. No 
immunocompromise with respect to certain viral or bacterial infections has been observed so far. 
 
Dimethylfumarate 
 
Dimethylfumarate (DMF) and other derivatives of fumaric acid ester compounds have been used for more than 
four decades to treat psoriasis [77] before the efficacy of this compound was also shown in MS [75]. DMF was 
approved as oral treatment for MS in 2013. The efficacy of DMF regarding reduction of relapse rate is probably 
comparable to fingolimod [75]. Fumaric acid esters, including DMF, have been shown to alter the activation 
state of DCs and shift the proinflammatory immune reaction to a Th2-like one [78] (see Table 1 and Fig. 1). 
Further activities include cytoprotective effects via induction of the transcription factor nuclear factor related 
factor 2 (Nrf2) [79] and the induction of regulatory B-cell subsets [80]. It can be anticipated that additional 
mechanisms of action will be identified based on the clinical observation of sometimes profound and long-
lasting lymphopenia in some patients. So far, no specific immunocompromise with respect to viral or bacterial 
infections has been reported, but a few PML cases have been observed [81]. 
 
Anti-CD52 (alemtuzumab) 
 
 A chimeric anti-CD52 monoclonal antibody (Campath-1) has been one of the first monoclonals used to treat 
human diseases, i.e. for hematopoietic malignancies such as non-Hodgkin lymphoma and chronic lymphatic 
leukemia, as well as for graft-versus-host disease [82, 83]. Campath-1 leads to prolonged depletion of CD52-
expressing lymphocytes, which includes a wide variety of T and B lymphocytes (see Table 1 and Fig. 1). 
Interestingly, the physiological role of CD52 is still not known. Compston, Coles and colleagues showed that 
Campath-1 efficiently blocks the inflammatory activity (relapses and new contrast-enhancing MRI lesions) in 
RRMS, among other effects by the lymphocyte depletion and relative dominance of CD4+CD25high regulatory 
T cells during reconstitution [84]. Based on these results, a humanized version of Campath-1, named 
alemtuzumab, was successfully tested in RRMS [34] and approved in 2014. Alemtuzumab significantly reduces 
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clinical and MRI disease activity [34]. Particularly, CD4+ T cells are depleted for long periods of time, and 
alemtuzumab is usually given only twice as short treatment courses in yearly intervals [85]. However, some 
patients require additional treatment courses, and surprisingly, approximately 30% of alemtuzumab-treated 
MS patients develop secondary autoimmune diseases, i.e. autoimmune thyroid disease, immune 
throbocytopenia or Goodpasture syndrome [86].  
 
Anti-CD20 (rituximab, ocrelizumab, ofatumumab) 
 
B-cell depleting therapies with anti-CD20 antibodies have provided evidence for an involvement of B cells in 
MS pathogenesis. Targeting B cells with the depleting antibody rituximab, a chimeric anti-CD20 monoclonal 
antibody, was first approached with the idea that B cells and their autoantibodies contribute to MS 
pathogenesis [30]. Rituximab had been developed and approved for treating B-cell malignancies and 
rheumatoid arthritis. CD20 is expressed on all B-cell differentiation stages except the very early and very late 
(plasma cells) ones. Rituximab depletes CD20-expressing B cells primarily via complement-mediated lysis and 
very effectively reduced inflammatory activity in RRMS, as shown by less contrast-enhancing MRI lesions [30] 
(see Table 1 and Fig. 1). Interestingly, this effect was observed already after 8 weeks of treatment, much earlier 
than would be expected, if a reduction of autoantibodies were the main effect. Humanized (ocrelizumab) and 
human (ofatumumab) anti-CD20 monoclonals have now been developed and shown high efficacy in RRMS in 
phase III (ocrelizumab) [87] and phase II studies [88] (summarized in [36]). Further, a subgroup analysis in the 
study by Hawker et al. [89] indicated that rituximab attenuates disease progression in primary progressive MS 
(PPMS) in patients younger than 51 years and with signs of disease activity by MRI. Recently, efficacy in PPMS 
has been shown formally for ocrelizumab [90]. Recent data on proinflammatory GM-CSF-secreting B cells 
support this notion [31]. In addition, leptomeningeal lymphoid follicular B-cell infiltrates associated with EBV 
activation have been observed in brain tissues from MS patients [91].  The frequent adjacent localization of 
cortical lesions suggests that factors produced in these leptomeningeal follicles reach the CNS parenchyma and 
damage myelin and neuronal cells in the vicinity [91].  These findings could provide an explanation for the 
observation of oligoclonal Ig production in the CSF and the frequent occurrence of grey matter lesions in MS 
patients [92]. 
 
Anti-CD25 (daclizumab) 
 
Daclizumab is a humanized monoclonal antibody against CD25, the alpha chain of the IL-2 receptor. It was 
originally approved for the prevention of allotransplant rejection with the concept that it would block the 
expansion of alloreactive T cells [93]. CD25 is found in the heterotrimeric high affinity IL-2 receptor complex 
composed of alpha- (CD25), beta- (CD127) and common gamma (CD132) chain [94]. Following promising 
observations in treatment-resistant uveitis [95], daclizumab was also used in IFN-non-responding RRMS 
patients and showed high efficacy regarding reduction of inflammatory MRI lesions [96]. Mechanistic studies 
along this trial documented that the effects of anti-CD25 treatment on T cells, including Treg cells, are only 
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modest, but a marked expansion of CD56bright NK cells was observed [97] (see Table 1 and Fig. 1). The expansion 
of CD56bright NK cells correlates strongly with the reduction of inflammatory lesions in the brain in multiple 
phase II and phase III studies. Interestingly, CD56bright NK cells do not exist in mice, and the expansion of an 
immune cell population with immunomodulatory, anti-viral and anti-tumor effects is a unique mechanism-of-
action compared with the above depleting antibodies [97]. Several other interesting mechanisms of action 
have been described for daclizumab, including inhibition of IL-2 transpresentation by DCs [98], and inhibition of 
LTi cell development [99]. Furthermore, a recent study not only corroborates prior data that CD56bright cells 
expand during daclizumab treatment and are capable to lyze activated CD4+ T cells directly [97], but adds to 
the mechanistic understanding by showing that daclizumab treatment corrects impaired interactions between 
DNAX accessory molecule (DNAM)-1 on NK cells and its ligand CD151 on CD4+ T cells [100]. A new formulation 
of daclizumab (daclizumab-HYP) has recently shown good clinical efficacy [35], and daclizumab-HYP was just 
approved by the Food and Drug Administration in May 2016. 
 
Autologous hematopoietic stem cell transplantation (aHSCT) 
Autologous hematopoietic stem cell transplantation (aHSCT) is used to reconstitute the immune system with 
autologous CD34+ hematopoietic precursor cells after, for example, myeloablative chemotherapy for various 
cancers. i.e. breast cancer [101]. aHSCT has also been explored as a treatment option in severe autoimmune 
diseases including MS for over 20 years now [102]. The idea is that a dysfunctional adaptive immune system 
can be eliminated by lympho- or myeloablative conditioning regimen (chemotherapy, previously whole body 
irradiation) and then be re-established with autologous CD34+ stem cells that had been collected from the 
patient prior to the chemotherapy. Initially, aHSCT was only used in advanced and highly active MS cases due 
to a mortality risk of 7% prior to 2000 [102]. Since 2000, the mortality has dropped to 1.2%, and now it will 
probably be even lower. Although no pivotal phase III trial has been performed yet, controlled phase II studies 
[103] and many case series indicate that aHSCT is highly efficacious in completely blocking MS disease activity 
for long periods of time and in the majority of patients [102, 104, 105]. Mechanistic studies showed that the 
concept of immune reconstitution by aHSCT is indeed correct in that the T-cell repertoire is completely 
renewed [106](see Table 1 and Fig. 1), and conventional and mucosal-associated invariant T (MAIT) cells are 
completely depleted [107], again strongly supporting the autoimmune pathogenesis of MS. 
 
Further MS treatment-related observations 
The study of other cytokines or inhibitors thereof aside from IFN-β as possible therapeutic targets, e.g. TNF-α 
inhibitors and the administration of IFN-γ, originally yielded promising results in EAE [108], but then not only 
failed in clinical translation, but also were associated with MS worsening. Increased levels of TNF-α in serum 
and CSF of MS patients correlate with disease severity, indicating a role for TNF-α in MS pathogenesis [109]. 
However, blocking TNF-α with lenercept, a recombinant soluble tumor necrosis factor receptor 1 (TNFR1) 
fusion protein, induced exacerbations of MS when compared with placebo controls [110].  In addition, onset of 
MS or demyelinating disease similar to MS has been reported in rheumatoid arthritis patients treated with a 
soluble TNFR2 fusion protein (etanercept) or with anti-TNF-α antibodies (infliximab) [111]. Interestingly, EAE 
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studies performed after the clinical trial have highlighted the pleiotropic effects of TNF-α and its two receptors, 
TNFR1 and TNFR2, in MS pathogenesis, and indicated that TNF-α signaling via TNFR2 on brain cells might be 
critical for repair processes in the CNS , beyond its proinflammatory effect (summarized in [112]).  
Similarly, the observations of a protective role of IFN-γ in EAE pathogenesis (summarized in [112]) failed to 
translate to MS, since the administration of IFN-γ was shown to aggravate the disease in MS patients [113].  
Follow-up studies in the EAE model have demonstrated that IFN-γ is involved in the pro-inflammatory 
responses e.g. augmenting MHC class I and II expression on glial cells, and interferes with repair processes in 
the brain [114].   
Further, IL-12 and IL-23 have been shown to have essential roles in the differentiation of pathogenic Th1 and 
Th17 cells inducing EAE [115].  Nevertheless, when Ustekinumab, an anti-human IL-12/IL-23p40 antibody, 
which is effective in psoriasis, was used in a phase II clinical trial of RRMS [116], it failed to show any 
therapeutic efficiency in the treated MS patients, in contrast to prior observations in EAE, where functional 
absence of IL12/IL23p40 fully abrogated the disease (summarized in [117]). Additional treatment attempts with 
cytokines (e.g. TGF-β), cytokine inhibitors (e.g. atacicept) and other approaches (e.g. altered peptide ligand) are 
mentioned in Table 1. Although the EAE models have helped to understand certain aspects of the 
immunopathogenesis of MS, these findings highlight that they failed to illustrate the entire complexity of the 
disease.    
 
Conclusions and Outlook 
 
Effective and unsuccessful MS therapies have further substantiated the concept of MS as a prototypic organ-
specific autoimmune disease, but at the same time they have underscored the notion of significant 
heterogeneity of disease processes in MS as well as differences in disease mechanisms between different 
autoimmune diseases. Neuropathologists have defined four distinct patterns of tissue injury in brain biopsy or 
autopsy tissue of MS patients based on characteristic signs of cellular or humoral immune components [13]. 
Thus, there is a need to increase efforts in further studying the highly complex disease processes underlying 
the different forms of MS.   
 
Based on the current knowledge, we hypothesize that the quantitative genetic trait of MS (with different 
numbers of risk alleles in individual patients), and particularly genes of the HLA-DR15 haplotype (DRB1*15:01, 
DRB5*01:01, DQA1*01:02, DQB1*06:02), together with environmental triggers cause a peripheral activation of 
CD4+ T cells. Upon entering the CNS, CD4+ T cells start a CNS-directed autoimmune disease, with additional 
immune cells (i.e. CD8+ T cells, B cells and antibodies, DCs, Treg cells) playing important roles during tissue 
damage, local antigen presentation in the CNS (DCs) or periphery (B cells), and maintaining or not peripheral 
immune tolerance (Treg cells) [1].  
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In this context, it will be important to perform detailed phenotypic and functional analysis of disease-relevant 
adaptive immune cells and tissues from MS patients. This will include expanding our knowledge on 
autoantigens possibly involved in MS pathogenesis beyond investigating T cells and B cells specifically targeting 
the myelin antigens causing EAE.  Besides examining peripheral blood T and B cells, we propose that significant 
efforts need to be undertaken to investigate the specificity of adaptive immune cells in the CSF and directly 
from the affected tissue, namely the brain and spinal cord parenchyma. Localization of T and B cells in these 
different CNS compartments and thus their migratory capacity will critically influence their contribution to MS 
pathogenesis.  
 
Immune cell trafficking to the CNS is a critical hallmark of MS and strictly controlled by the BBB and the 
epithelial blood-cerebrospinal fluid barrier (BCSFB), which protect the CNS from the constantly changing milieu 
in the blood stream [118]. While CNS parenchyma in healthy individuals is completely devoid of T and B cells, 
the CSF space although harboring 10 to 100-fold less cells than other sterile body fluids (e.g. synovial or pleural 
fluid), is characterized by the presence of a high proportion of TCM and TEM cells (summarized in [119]). This 
underscores that T cells routinely cross the BBB and BCSFB and enter the CSF space from where they maintain 
immune surveillance of the CNS. In the absence of local activation, these T cells remain separated from the CNS 
parenchyma by the glia limitans, which establishes a second tissue barrier that is lacking in all other organs 
[120]. Based on recent observations that immune-deficient mice suffer from cognitive deficits and that certain 
T-cell subsets even exert neuroprotective effects, it has even been proposed that CSF T cells may actively 
contribute to tissue homeostasis [121] and thus the term „protective autoimmunity“ was coined to describe 
the contribution of CNS-specific CD4+ T cells to the protection of the CNS [122]. The anatomical routes and 
molecular mechanisms involved in T cell trafficking into the CSF spaces during CNS immunosurveillance, and 
how they change during MS are still incompletely understood and need further investigation.  
In this context it is however important that CSF drains from the subarachnoid space via lymphatic vessels in the 
nasal mucosa [123, 124, 125] and via dural lymphatics [126, 127] into the deep cervical lymph nodes and hence 
to the extracerebral immune system. CNS antigens may thus become available to the peripheral immune 
system via these drainage routes. The observation by Stern et al. [128] that B cells, which populate MS brain 
tissue, mature in draining cervical lymph nodes supports this notion and indicates that the recognition of brain-
derived antigen may involve not only the above mentioned lymphatic structures, but also antigen presentation 
in the draining cervical lymph nodes. 
 
Natalizumab-treated MS patients show significantly reduced counts of both CD4+ and CD8+ T-cell subsets in 
their CSF [129], arguing that natalizumab blocks CNS entry of both, CD4+ and CD8+ T-cell subsets and that 
reducing the CSF pool of T cells interferes with CNS immunosurveillance. The increased risk for PML observed 
under natalizumab therapy has supported this notion; however, it completely fails to explain how reduced CNS 
immune surveillance will establish a specific risk for infection to one single virus. Further insights into these 
mechanisms rely on continuous research with the patients' cells as outlined above.  
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Understanding the anatomical routes and molecular mechanisms guiding different T-and B-cell subsets into the 
CNS during immunosurveillance and neuroinflammation, as well as examining their specificity and function will 
thus set the stage to more accurately foresee CNS specific adverse effects of the increasing numbers of 
therapies targeting T-cell trafficking or even depleting T cells in MS. Additionally, this will allow to identify novel 
therapeutic targets at the level of the brain barriers suited to specifically block CNS recruitment of destructive T 
cells, while leaving the migration of protective T-cell subsets into the CNS unaffected. 
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Figure Legends 
 
Figure 1. Schematic representation of the putative cellular and molecular therapeutic targets used in  the MS 
treatment .  
(Left) Cellular and molecular targets in the periphery (lymph nodes, bone marrow and the respective immune 
cells).  (Center) The endothelial BBB (red endothelial cells) at the postcapillary venule level with a perivascular 
space and the glia limitans including astrocytes (green). (Right) Inflamed CNS parenchyma with a neuron 
(yellow) and its myelinated axon and the oligodendrocyte (blue) is shown, in addition to infiltrating immune 
cells (APC, Th1, Th2, Th17 and macrophages). Immune cell interactions are shown with two headed black 
arrows, red arrows indicate therapeutic targets and T shaped lines (red) indicate blocking of pathways. Cells 
depleted by monoclonal antibodies are indicated with the gray shade around the respective cells target.  
Abbreviations: aHSCT, autologous hematopoietic stem cells transplantation; FTY720, Fingolimod; NTZ, 
Natalizumab; IFNβ, Interferon β; DMF, Dimethylfumarate; GA, Glatiramer Acetate; APC, antigen presenting cell; 
BBB, blood-brain barrier; CNS, central nervous system, PC = plasma cell, MΦ-macrophage 
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Table 1 
 
Table 1: Treatments tested for MS: efficacy, mechanisms of action, general and specific side effects and lessons learnt. 
 
Treatment Efficacy in MS Main mechanism/s of action Important side effects/findings in 
MS 
Lessons learnt/questions 
Autologous 
hematopoietic stem 
cell transplantation 
(aHSCT) 
Very High Removes the entire adaptive immune system 
by the conditioning regimen and re-
establishes a new T cell repertoire from 
CD34+ hematopoietic precursor cells 
Treatment-related mortality due 
to infections immediately post-
transplantation approximately 
0.5-1%; only suited for very active 
patients; not approved yet 
Removes a pathogenic T cell repertoire; 
thymic function is induced; new T cell 
repertoire is established; effects on the B 
cell repertoire/ antibodies less clear 
 
Anti--integrins 
(natalizumab) 
High Blocks entry of activated T cells/immune cells 
into the CNS (CD4+>>CD8+ T cells); releases 
certain B cell maturation stages and bone 
marrow precursor cells into the peripheral 
blood 
Very well tolerated, but > 600 
cases of PML  (> 20% with fatal 
outcome); without major risks in 
JCVnegative individuals 
Intervention with specific steps of 
immune response and target organ 
surveillance can lead to problems with 
very specific pathogens and the 
complications associated with them; high 
efficacy due to interference with a critical 
step in MS pathogenesis 
 
Anti-CD52 
(alemtuzumab) 
  
High Elimination of large fractions of T- and B cells; 
among them pathogenic T- and B cells; only 
few therapy cycles needed; not clear, which 
treatments could be used after alemtuzumab
    
30-40% of patients develop 
secondary autoimmune diseases; 
acute infusion reactions due to 
cell lysis 
Reasons for the induction of secondary 
autoimmune diseases not understood; 
long term effects of cell depletion not 
known 
Anti-CD20* 
(rituximab, 
ocrelizumab, 
ofatumumab) 
High Depletes a large part of the B cell lineages; 
removes pro-inflammatory B cells and their 
antigen-presenting function; role of 
antibodies in the response to this treatment 
less clear 
Acute infusion reactions; drug 
sensitization; PML (but so far only 
in other autoimmune diseases); 
others 
Mechanism of its high efficacy in MS not 
fully understood yet, but most likely due 
to inhibition of antigen-presenting 
function of B cells; first approach with 
activity in PPMS 
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Treatment Efficacy in MS Main mechanism/s of action Important side effects/findings in 
MS 
Lessons learnt/questions 
Anti-CD25* 
(daclizumab-Hyp) 
 
Moderate/High Induces the expansion of immunoregulatory 
NK (CD56bright) cells; inhibition of T cell 
activation via blocking CD25 on DCs; others 
Skin reactions; liver enzyme 
elevation; upper respiratory 
infections 
Blocking/knocking out IL-2 or its 
components in mouse models led to 
severe autoimmunity or 
immunodeficiency; CD56bright NK cells do 
not exist in mice 
 
Fingolimod 
(unspecific S1P-R 
agonist/functional 
antagonist) 
Moderate Traps naive and central memory T cells in 
lymph nodes; effects on many other cells and 
tissues including the BBB due to expression of 
S1P receptors 
Lymphopenia; macular edema; 
pre-cancerous skin lesions; drop in 
blood pressure and heart rate; 
lymphopenia; PML (rare); others
  
The immunologic effects of this 
compound causes an albeit subtle 
compromise of immune control of 
persistent/latent infection with HSV-1 and 
VZV; a few fatal cases have been reported 
 
Dimethylfumarate Moderate Th1-Th2 shift by modulating DC function; anti-
oxidative activity via Nrf2 induction; inhibition 
of NF-κB-induced genes 
Gastrointestinal side effects; flush; 
in some patients long- lasting 
lymphopenia; elevation of liver 
enzymes; PML (rare); others 
 
Works well in psoriasis; reason of long-
lasting lymphopenias not known 
IFN-β Low/Moderate Inhibition of matrix metalloproteases; Th1-
Th2 shift; influence on antigen presentation; 
antiviral activities (relevant for the treatment 
of MS?); others 
 
Very well tolerated; skin reactions; 
flu-like symptoms transient liver 
enzyme increase 
This type I interferon has multiple 
immunomodulatory effects besides its 
antiviral activities 
Glatiramer-acetate Low/Moderate Affects antigen presentation; Th1-Th2 shift; 
induces neurotrophic factors and CD8+ Tregs; 
others 
Very well tolerated; flush; 
lipoatrophy at injection sites 
Peptidic mixture that was developed to 
induce EAE; effects are similar to those of 
altered peptide ligands 
 
Teriflunomide Low/Moderate Inhibition of dihyroorotate-synthetase; 
inhibition of activated/growing cells 
Nausea, diarrhea, alopecia, low 
neutrophils; liver enzyme 
elevation; hypertension; 
teratogenic 
 
Metabolite of leflunomide; which is in use 
in rheumatoid arthritis 
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Treatment Efficacy in MS Main mechanism/s of action Important side effects/findings in 
MS 
Lessons learnt/questions 
IFN-γ Worsened 
disease 
Primary Th1 cytokine; given with the idea of 
mediating anti-viral effects; induces 
proinflammatory immune reactions 
 
Induction of MS relapses Strongly supports the role of Th1 cells as 
major pathogenic cells in MS 
TNF inhibition by 
sTNFR-IgG p55 
Worsened 
disease 
Blocks interaction of TNF with TNF-receptors; 
ameliorated EAE 
Induction/prolongation of MS 
relapses 
Demonstrated that inhibition of cyto- 
kines with pleiotropic effects is 
complicated; the fusion protein inhibited 
both proinflammatory (mediated by 
TNFR1) and remyelinating/repair-fostering 
(mediated by TNFR2) effects of TNF 
 
TGF-β  None Was given with the idea to mediate 
immunoregulatory effects; ameliorated EAE 
Severe compromise of kidney 
function (drop in glomerular 
filtrating rate) during phase I 
testing in MS 
 
Has too many other effects than immune 
regulation; not suited as 
immunomodulatory treatment 
Altered peptide ligand 
(APL) 
Worsened 
disease 
APLs showed ameliorating effects in EAE 
models; given in MS with the idea to 
antagonize autoreactive T cells or to induce a 
Th1-Th2 shift 
Induction of relapses; local 
reactions 
Relapses were caused by APL-specific Th1 
cells cross-reacting with native MBP 
peptide strongly supporting a role of 
myelin-specific Th1 cells in MS  
Anti-IL-12/-23 
p40(ustekinumab) 
None Shows therapeutic afficacy in psoriasis; 
ameliorated EAE; was used in MS with the 
idea to inhibit pathogenic Th17 cells 
Does not apply Lack of efficacy questions a role of Th17 
cells in MS, since these cells play a major 
role in psoriasis 
 
Anti-BAFF/APRIL 
(atacicept; a fusion 
protein of TACI, the 
transmembrane 
receptor that binds 
BAFF and APRIL with 
the Fc portion of IgG) 
Worsened 
disease 
Was used to block B cells assuming that B cell 
activation/proliferation plays an important 
role in MS 
Increased the relapse rate in 
RRMS 
Since this approach appears effective in 
SLE, where antibodies play a key 
pathogenic role, the B cell-associated 
pathomechanisms in SLE and MS must be 
different. So far, the failure of Atacicept in 
MS is not understood. 
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* filed for approval in MS; already approved in some countries 
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